Price Alert

Sera Prognostics Inc. (SERA)

NASDAQ: SERA · Real-Time Price · USD

3.09

0.14 (4.75%)

At close: Sep 26, 2025, 3:59 PM

3.20

3.56%

After-hours: Sep 26, 2025, 06:58 PM EDT

4.75% (1D)

Bid	2.69
Market Cap	114.62M
Revenue (ttm)	108K
Net Income (ttm)	-32.73M
EPS (ttm)	-0.85
PE Ratio (ttm)	-3.64
Forward PE	-3.81
Analyst	n/a
Dividends	n/a

Ask	3.11
Volume	53,161
Avg. Volume (20D)	282,966
Open	3.02
Previous Close	2.95
Day's Range	2.93 - 3.10
52-Week Range	1.37 - 9.13
Beta	1.00
Ex-Dividend Date	n/a

About SERA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SERA

Website n/a

Full Company Profile

Next Earnings Release

Sera Prognostics Inc. is scheduled to release its earnings on Nov 5, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

7 months ago

-9.44%

Sera Prognostics shares are trading lower after th... Unlock content with Pro Subscription

News

1 month ago · seekingalpha.com

Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript

Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Austin Aerts - Chief Financial Officer Evguenia Lindgardt - President, CEO & Direc...

1 month ago · fool.com

Sera Prognostics (SERA) Q2 Loss Down 4%

Sera Prognostics (SERA 12.24%), a diagnostic company specializing in pregnancy risk prediction, reported Q2 2025 results on August 6, 2025. The company's headline news was a net loss improvement and c...

1 month ago · zacks.com

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.25 per share a year ago.

2 months ago · seekingalpha.com

Sera Prognostics: PreTRM Labor Test Should Represent Advance In Risk Assessment

Sera Prognostics' PreTRM test shows strong clinical utility in reducing neonatal morbidity and NICU admissions, outperforming standard cervical length screening. The company is well-capitalized with $...